L

Laboratorios Richmond SACIF
BCBA:RICH

Watchlist Manager
Laboratorios Richmond SACIF
BCBA:RICH
Watchlist
Price: 1 995 ARS 2.31% Market Closed
Market Cap: 161.1B ARS
Section:
 

Relative Value

The Relative Value of one RICH stock under the Base Case scenario is hidden ARS. Compared to the current market price of 1 995 ARS, Laboratorios Richmond SACIF is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RICH Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
26
vs Industry
63
Median 3Y
1.5
Median 5Y
1.3
Industry
2.6
More Details
11.3
P/E
P/E
Price to Earnings
11.3
vs History
50
vs Industry
42
Median 3Y
6.1
Median 5Y
11.2
Industry
21.4
More Details
23.2
P/OCF
P/OCF
Price to OCF
23.2
vs History
15
vs Industry
4
Median 3Y
-7.7
Median 5Y
2.5
Industry
16.4
More Details
23.8
P/FCFE
P/FCFE
Price to FCFE
23.8
vs History
15
vs Industry
22
Median 3Y
-3.3
Median 5Y
5
Industry
22.8
More Details
2.1
P/B
P/B
Price to Book Value
2.1
vs History
66
vs Industry
34
Median 3Y
2.2
Median 5Y
2.6
Industry
2.2
More Details
3
EV/S
EV/S
Enterprise Value to Sales
3
vs History
9
vs Industry
41
Median 3Y
2.6
Median 5Y
2.2
Industry
2.9
More Details
5.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.1
vs History
26
vs Industry
41
Median 3Y
5
Median 5Y
4.5
Industry
5.5
More Details
10.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.6
vs History
44
vs Industry
29
Median 3Y
12
Median 5Y
9.5
Industry
13
More Details
15.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15.9
vs History
38
vs Industry
26
Median 3Y
16
Median 5Y
13.4
Industry
16.5
More Details
45.4
EV/OCF
EV/OCF
Enterprise Value to OCF
45.4
vs History
12
vs Industry
3
Median 3Y
-11.4
Median 5Y
3
Industry
15.6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-10.2
Median 5Y
-9.2
Industry
18.7
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
68
vs Industry
52
Median 3Y
1.1
Median 5Y
1.2
Industry
1.9
More Details

Multiples Across Competitors

RICH Competitors Multiples
Laboratorios Richmond SACIF Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AR
Laboratorios Richmond SACIF
BCBA:RICH
161.1B ARS 1.5 11.3 10.6 15.9
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.2 108.4 158.6
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
AR
L
Laboratorios Richmond SACIF
BCBA:RICH
Average P/E: 22.9
11.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AR
L
Laboratorios Richmond SACIF
BCBA:RICH
Average EV/EBITDA: 400.7
10.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AR
L
Laboratorios Richmond SACIF
BCBA:RICH
Average EV/EBIT: 1 713.6
15.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
RICH intrinsic value, competitors valuation, and company profile.
DCF Valuation
RICH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RICH stock valuation using valuation multiples.
Wall Street Estimates
RICH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RICH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 306,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.